Assessment of lipid spectrum and C-reactive protein in people working in the Arctic zone of Russia
https://doi.org/10.47183/mes.2023.048
Abstract
Adaptation to the extreme living conditions of the North causes dyslipidemia, a risk factor for cardiovascular diseases (CVD), in people working there. This study aimed to assess the level of lipids and C-reactive protein (CRP), a marker of inflammation in CVD cases, in the blood of men staying in the Arctic and Subarctic zones of Russia. Accordingly, the sample was divided into two group, Arctic and Subarctic, the former included 51 participants, aged 35.7 ± 0.6 years, the latter — 54 individuals, aged 34.2 ± 0.9 years (p = 0.167); the duration of their work/stay in the Arctic and Subarctic zones was 7.1 ± 0.2 and 6.4 ± 0.6 years (p = 0.447), respectively. We sampled blood of the participants and measured triglycerides, total cholesterol, low (LDL) and high (HDL) density lipoproteins, atherogenic index (AI), CRP content. Arctic group had higher levels of triglycerides (1.71 ± 0.03 and 1.38 ± 0.14 mmol/l, p = 0.021), total cholesterol (6.15 ± 0.08 and 5.47 ± 0.14 mmol/l, p =0.001), HDL (1.5 ± 0.06 and 1.1 ± 0.04 mmol/l, p = 0.001); the values of LDL did not differ significantly between the groups (4.07 ± 0.08 and 4.1 ± 0.15 mmol/l, p = 0.88), and AI and CRP values (3.41 ± 0.18 and 4.18 ± 0.2, p = 0.007; 3.41 ± 0.18 and 4.91 ± 0.22 mg/l, p = 0.006, respectively) were greater in the Subarctic group. By triglycerides, dyslipidemia was diagnosed in 49.0% and 18.4% of Arctic and Subarctic participants, respectively, by total cholesterol — in 98.0% and 57.8%, by LDL — in 94.1% and 88.0%. As for HDL, their level was lower than normal in 2.0% of the Arctic group subjects and 36.7% of the Subarctic group subjects, which means a higher risk of cardiovascular diseases in the Subarctic region. The level of CRP indicated that 90% of the Arctic group participants were at risk of CVD (moderate risk for 23.5%, high risk for 66.7%), and in the Subarctic group this number was 100% (moderate risk for 7.7%, high risk for 88.5%). The likely reasons behind this are the specifics of nutrition and living conditions. Program of prevention of CVD in the Arctic zone should include lipid profile and CRP tests as part of every periodic medical examination, regardless of age. It is necessary to implement dyslipidemia alimentary correction measures.
About the Authors
D. A. NarutdinovRussian Federation
Krasnoyarsk
R. S. Rakhmanov
Russian Federation
Nizhny Novgorod
E. S. Bogomolova
Russian Federation
Nizhny Novgorod
S. A. Razgulin
Russian Federation
Nizhny Novgorod
N. N. Potekhina
Russian Federation
Nizhny Novgorod
References
1. Kukharchuk VV, Ezhov MV, Sergienko IV, Arabidze GG, Balakhonova TV, Gurevich VS, et al. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journ. 2020; 2: 6–29. DOI: 10.38109/2225-1685-2020-2-6-29. (Russian).
2. Utkina EA, Afanasyeva OI, Pokrovsky SN. C-reactive protein: pathogenetic characteristics and possible therapeutic target. Russian Journal of Cardiology. 2021; 26 (6): 4138. DOI: 10.15829/1560-4071-2021-4138. (Russian).
3. Melnikov IS, Kozlov SG, Saburova OS, Avtaeva YN, Guria KG, Gabbasov ZA. Monomeric C-reactive protein in atherosclerotic cardiovascular disease: advances and perspectives. Int J Mol Sci. 2023 Jan 20; 24 (3): 2079.
4. Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Gordon Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. J Cell Physiol. 2018; 233 (11): 8508–25. DOI:10.1002/jcp.26791.
5. Shah PK. Inflammation, infection and atherosclerosis. Trends Cardiovasc Med. 2019; 29 (8): 468–72. DOI: 10.1016/j.tcm.2019.01.004.
6. Adukauskienė D, Čiginskienė A, Adukauskaitė A, Pentiokinienė D, Šlapikas R, Čeponienė I. Clinical relevance of high sensitivity C-reactive protein in cardiology Medicina (Kaunas). 2016; 52 (1): 1–10. DOI: 10.1016/j.medici.2015.12.001.
7. Nagibovich OA, Ukhovsky DM, Zhekalov AN, et al. Mechanisms of hypoxia in Arctic zone of Russian Federation. Bulletin Of The Russian Military Medical Academy. 2016; 2 (54): 202–5. (Russian).
8. Sevostyanova YV. Some features of human lipid and carbohydrate metabolism in the North. Bulletin of Siberian Medicine. 2013; 12 (1): 93–100. (Russian).
9. Kurkatov SV, Tikhonova IV, Ivanova OYu. Assessment of the risk of environmental atmospheric pollutants for the health of the population of the city of Norilsk. Hygiene and Sanitation. 2015; 94 (2): 28–31. (Russian).
10. Revich BA. Riski zdorov'yu naseleniya v «goryachikh tochkakh» ot khimicheskogo zagryazneniya Arkticheskogo makroregiona. Problemy prognozirovaniya. 2020; 2: 148–57. (Russian).
11. Hazova EV, Bulashova OV, Amirov NB. Is it necessary to determine highly sensitive C-reactive protein in patients with chronic heart failure: clinical and prognostic aspects. Bulletin of contemporary clinical medicine. 2022; 15 (4): 54–9. DOI: 10.20969/VSKM.2022. (Russian).
12. Kramer F, Voss S, Roessig L, et al. Evaluation of highsensitivity C-reactive protein and uric acid in vericiguattreated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020; 22 (9): 1675–83. DOI: 10.1002/ejhf.1787.
13. Postanovlenie Pravitel'stva RF ot 29.12.2007 № 946 (red. ot 18.09.2020) «O prodovol'stvennom obespechenii voennosluzhashchikh i nekotorykh drugikh kategoriy lits, a takzhe ob obespechenii kormami (produktami) shtatnykh zhivotnykh voinskikh chastey i organizatsiy v mirnoe vremya». (Russian).
14. Federal'nyy zakon ot 13.07.2020 №193-FZ «O gosudarstvennoy podderzhke predprinimatel'skoy deyatel'nosti v Arkticheskoy zone Rossiyskoy Federatsii». (Russian).
15. Gridin LA, Shishov AA, Dvornikov MV. Features adaptation reactions of human in Far North. Public Health and Life Environment. 2014; 4 (253): 4–6. (Russian).
16. Deputat IS, Deryabina IN, Nekhoroshkova AN, Gribanov AV. Effect of Climatic and Ecological Conditions of the North on Ageing Processes. Journal of Medical and Biological Research. 2017; 5 (3): 5–17. (Russian).
17. Chashchin VP, Gudkov AB, Chashchin MV, Popova ON. Predictive Assessment of Individual Human Susceptibility to Damaging Cold Exposure. Human Ecology. 2017; 5: 3–13. (Russian).
18. Polyakova EM, Chashchin VP, Meltser AV. Risk factors causing health disorders among workers involved in oil extraction and performing their working tasks outdoors during a cold season. Health Risk Analysis. 2019; 4: 84–92. (Russian).
19. Polyakova EM, Meltser AV. Сomparative analysis of health status of employees working in an open territory in t cold period of the year according to questionnaire results. Preventive and clinical medicine 2019; 4 (73): 35–44. (Russian).
20. Morris DM, Pilcher JJ, Powell RB. Task-dependent cold stress during expeditions in Antarctic environments. Int J Circumpolar Health. 2017; 76 (1): 1379306. DOI:10.1080/22423982.2017.13 79306.
21. Gudkov AB, Popova ON, Nebuchennyh AA, Bogdanov MYu. Ecological and physiological characteristic of the Arctic climatic factors. Review. Marine medicine. 2017; 3 (1): 7–13. (Russian).
22. Panin LE. Lipoprotein metabolism and atherosclerosis. The Siberian Scientific Medical Journal. 2006; 2 (120): 15–22. (Russian).
23. Krivoshapkina ZN, Mironova GE, Semenova EI, Olesova LD, Yakovleva AI. Pokazateli lipidnogo obmena u prishlykh zhiteley Yakutii v zavisimosti ot srokov prozhivaniya na Severe. Yakutskiy meditsinskiy zhurnal. 2018; 2: 28–30. DOI: 10.25789/YMJ.2018.62.09. (Russian).
24. Gurevich VS, Koziolova NA, Ezhov MV, Sergienko IV, Аlieva AS, Vavilova TV, et al. Unsolved problems of dyslipidemia and residual cardiovascular risk. The Journal of Atherosclerosis and Dyslipidemias. 2022; 1 (46): 31–9. DOI: 10.34687/2219-8202.JAD.2022.01.0003. (Russian).
25. Poteryaeva ON, Usynin IF. Dysfunctional high-density lipoproteins in diabetes mellitus. Problems of endocrinology. 2022; 68 (4): 69– 77. DOI: 10.14341/probl13118. (Russian).
26. Wong N, Nicholls S, Tan J, Bursill C. The role of high-density lipoproteins in diabetes and its vascular complications. Int J Mol Sci. 2018; 19 (6): 1680. DOI: 10.3390/ijms19061680.
27. Ageykin AV, Almakaeva AD. Lipoproteidy vysokoy plotnosti kak glavnyy antiaterogennyy faktor razvitiya ateroskleroza. Molodoy uchenyy. 2015; 1 (81): 139–41. (Russian).
28. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013; 62 (5): 397–408. DOI: 10.1016/j.jacc.2013.05.016.
29. Denegri A, Boriani G. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Curr Pharm Des. 2021; 27 (2): 263–75. DOI: 10.2174/1381612826666200717090334.
30. Boncler M, Wu Y, Watala C. The Multiple Faces of C-Reactive Protein-Physiological and Pathophysiological Implications in Cardiovascular Disease. Molecules. 2019; 24 (11): 2062. DOI: 10.3390/molecules24112062.
Review
For citations:
Narutdinov D.A., Rakhmanov R.S., Bogomolova E.S., Razgulin S.A., Potekhina N.N. Assessment of lipid spectrum and C-reactive protein in people working in the Arctic zone of Russia. Extreme Medicine. 2023;25(4):116-122. https://doi.org/10.47183/mes.2023.048